Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population
NCT04530656Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (12 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Adverse Reactions at 7 days. Started Aug 2020; status: completed.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04530656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530656.